Lilly buys rights to Axiron from Acrux; Merck & Co returns Ostarine to GTx; Boehringer deal with 4-Antibody AG

16 March 2010

It has been a busy couple of days on the drug licensing front, with US drug major Eli Lilly announcing an agreement yesterday with Australia's Acrux, Germany's Boehringer Ingelheim entering an accord this morning with Swiss biotechnology firm 4-Antobody AG and drug giant Merck & Co dropping plans to develop GTx' Ostarine (MK-2866), an investigational selective androgen receptor modulator (SARM).

Lilly revealed that it has entered into an exclusive worldwide license agreement for the potential commercialization of Acrux' experimental underarm testosterone solution (proposed trade name Axiron), for which a New Drug Application is currently under regulatory review by the US Food and Drug Administration for the treatment of testosterone deficiency (hypogonadism) in men.

Potential $335 million for Acrux

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK